Working…
ClinicalTrials.gov
ClinicalTrials.gov Menu

Inotuzumab Ozogamicin - PF-05208773

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
 
ClinicalTrials.gov Identifier: NCT03127605
Expanded Access Status : Approved for marketing
First Posted : April 25, 2017
Last Update Posted : May 18, 2020
Sponsor:
Information provided by (Responsible Party):
Pfizer

Brief Summary:
Inotuzumab Ozogamicin Expanded Access Program

Intervention/treatment
Drug: Inotuzumab Ozogamicin

Layout table for study information
Study Type : Expanded Access
Expanded Access Type : Individual Patients

Resource links provided by the National Library of Medicine



Intervention Details:
  • Drug: Inotuzumab Ozogamicin
    Other Name: PF-05208773

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Layout table for eligibility information
Ages Eligible for Study:   Child, Adult, Older Adult
Criteria

Inclusion Criteria:

-

Exclusion Criteria:

-


No Contacts or Locations Provided
Layout table for additonal information
Responsible Party: Pfizer
ClinicalTrials.gov Identifier: NCT03127605    
Other Study ID Numbers: B193
First Posted: April 25, 2017    Key Record Dates
Last Update Posted: May 18, 2020
Last Verified: May 2020
Additional relevant MeSH terms:
Layout table for MeSH terms
Inotuzumab Ozogamicin
Antineoplastic Agents